Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Filgotinib (Primary) ; Lanraplenib (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 08 Sep 2021 Primary endpoint (Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12) has not been met, according to Results published in the Rheumatology.
- 08 Sep 2021 Results published in the Rheumatology
- 16 Jan 2020 Status changed from active, no longer recruiting to completed.